Drugs / Biostate
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00879541 | Feb 2009 → Oct 2010 | hemophilia A | CSL Behring | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00941616 | Jun 2009 → Feb 2012 | von Willebrand disease (hereditary or acquired) | CSL Behring | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT01445197 | Dec 2012 → Dec 2013 | hemophilia A | CSL Behring | Terminated | No outcome recorded |
| Phase 3 | NCT01224808 | Oct 2010 → Mar 2014 | von Willebrand disease (hereditary or acquired) | CSL Behring | Completed | No outcome recorded |
| Phase 3 | NCT01213446 | Aug 2010 → Aug 2013 | von Willebrand disease (hereditary or acquired) | CSL Behring | Completed | No outcome recorded |
| Phase 3 | NCT01229007 | Aug 2010 → Jul 2014 | hemophilia A | CSL Behring | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2010-02-04 | CSL Behring | Global SWIFT Studies Will Evaluate Safety and Efficacy of CSL Behring’s Biostate® for von Willebrand Disease and Hemophilia csl.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Biostate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00941616 ↗ |
| Action | Restore | “given for replacement therapy” NCT01445197 ↗ |
| Modality | Protein / enzyme biologic | “Human Coagulation Factor VIII / von Willebrand Factor” NCT00879541 ↗ |
| Route | Intravenous | “Single bolus intravenous dose of 50 IU/kg” NCT00879541 ↗ |